Asset Publisher

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies are listed below. If there are no policies listed, it means there are currently no policies in draft status.

The drugs below require that a member’s medical condition meets the policy requirements prior to being given (precertification) unless otherwise specified. Providers must submit a request for pre-service review in order to be approved. If the provider does not receive approval for precertification, the plan will pay no benefits.

Precertification is required for these provider-administered drugs when administered in a provider’s office, outpatient facility or home health setting. Precertification does not apply to inpatient hospital claims at this time. Exceptions to this include: Luxturna, Kymriah and Yescarta, which require a precertification for any place of treatment.

Members can request a copy of a full drug policy by calling the Customer Service number on their ID card.

Comment on Draft Drug Policies

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies.

We accept comments for 45 days from the posting date listed on the draft policy.

Make sure your voice is heard by providing feedback directly to us:
 

Credence Blue Cross and Blue Shield Service Center
Attn: Pharmacy Department
P.O. Box 10447
Birmingham, AL 35202

Fax: 205-220-9576

Draft Provider-Administered Drug Policies

Draft policies are listed below. If there are no policies listed, it means there are currently no policies in draft status.

 

Note: Coverage is subject to member's specific benefits. Group specific policies will supersede these policies when applicable. Please refer to member's benefit plan.

Comment on Draft Drug Policies

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to draft policies.

Comments are accepted for 45 days from the posting date listed on the draft policy.

Make sure your voice is heard by providing feedback directly to us:

Birmingham Service Center
Attn: Health Management — Medical Policy
P.O. Box 10527
Birmingham, AL 35202


Fax: 205-220-0878

Policy # Policy Title Print View
PH-1234 Inhaled Antibiotics Duplicate Therapy Prior Authorization with Quantity Limit Program Summary
PH-90089 Nplate® (romiplostim)
PH-90109 Rituximab: Rituxan®, Truxima®, Ruxience®, Riabni™
PH-90117 Ustekinumab: Stelara®; Wezlana™; Selarsdi™; Pyzchiva®; Otulfi™; Imuldosa®; Ustekinumab-aekn§
PH-90177 Ilaris® (canakinumab)
PH-90242 Aranesp® (darbepoetin alfa) (Precertification Not Required)
PH-90243 Epoetin alfa: Epogen®; Procrit®; Retacrit™
PH-90244 Mircera® (methoxy polyethylene glycol-epoetin beta) (Precertification not required)
PH-90260 Nucala® (mepolizumab)
PH-90350 Luxturna® (voretigene neparvovec-rzyl)
PH-90468 Zolgensma® (onasemnogene abeparvovec-xioi)
PH-90481 Spravato® (esketamine)
PH-90513 Adakveo® (crizanlizumab-tmca)
PH-90514 Givlaari (givosiran)
PH-90579 Oxlumo® (lumasiran)
PH-90598 Abecma® (idecabtagene vicleucel)
PH-90674 Spevigo® (spesolimab)
PH-90677 Skysona® (elivaldogene autotemcel)
PH-90713 Elevidys® (delandistrogene moxeparvovec-rokl)
PH-90734 Omvoh™ (mirikizumab-mrkz)
PH-90743 Lyfgenia® (lovotibeglogene autotemcel)
PH-90744 Casgevy™ (exagamglogene autotemcel)
PH-90751 Lenmeldy™ (atidarsagene autotemcel)
PH-90769 Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs)
PH-90781 Ryoncil® (remestemcel-L-rknd)
VP-0778 Ziihera® (zanidatamab-hrii)
VP-0779 Bizengri® (zenocutuzumab-zbco)
VP-0780 Unloxcyt® (cosibelimab-ipdl)
VP-0784 Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy)
VP-90004 Adcetris® (brentuximab vedotin)
VP-90038 Erbitux® (cetuximab) (Intravenous)
VP-90043 Fulvestrant: Faslodex®; Fulvestrant Ψ (Intramuscular)
VP-90130 Bendamustine: Treanda®; Bendeka®; Belrapzo®; Vivimusta™; Bendamustine Ψ
VP-90136 Vectibix® (panitumumab) (Intravenous)
VP-90148 Yervoy™ (ipilimumab) (Intravenous)
VP-90209 Keytruda® (pembrolizumab)
VP-90226 Opdivo® (nivolumab)
VP-90256 Onivyde® (irinotecan liposome injection)
VP-90266 Darzalex™ (daratumumab)
VP-90274 Imlygic® (talimogene laherparepvec)
VP-90278 Tecentriq® (atezolizumab)
VP-90295 Bavencio® (avelumab) (Intravenous)
VP-90301 Imfinzi™ (durvalumab) (Intravenous)
VP-90322 Rituxan Hycela® (rituximab and hyaluronidase human)
VP-90398 Libtayo® (cemiplimab-rwlc) (Intravenous)
VP-90482 Polivy® (polatuzumab vedotin-piiq)
VP-90521 Padcev® (enfortumab vedotin-ejfv) (Intravenous)
VP-90531 Jelmyto® (mitomycin)
VP-90532 Trodelvy® (sacituzumab govitecan-hziy)
VP-90581 Danyelza® (naxitamab-gqgk) (Intravenous)
VP-90599 Jemperli® (dostarlimab-gxly)
VP-90683 Imjudo® (tremelimumab-actl) (Intravenous)
VP-90691 Adstiladrin® (nadofaragene firadenovec-vncg)
VP-90692 Lunsumio™ (mosunetuzumab-axgb)
VP-90700 Zynyz™ (retifanlimab-dlwr) (Intravenous)
VP-90735 Loqtorzi™ (toripalimab-tpzi) (Intravenous)
VP-90750 Tevimbra™ (tislelizumab-jsgr)
VP-90753 Anktiva® (nogapendekin alfa inbakicept-pmln)
VP-90756 Imdelltra™ (tarlatamab-dlle)